Valneva Faces a Pivotal Week as Legal Probe Casts Shadow Over Q1 Results

The French biotech group Valneva is heading into its first-quarter earnings report on May 13 with a freshly padded balance sheet but a legal cloud hanging overhead. The company completed a private placement earlier this month, raising €37 million upfront with the potential for an additional €47 million through the exercise of warrants, bringing the total capital injection to as much as €84 million. The move shores up Valneva’s cash runway through 2026, but existing shareholders are absorbing a roughly 9% dilution.

That financial cushion comes just as the company faces a formal investigation by US law firm Pomerantz LLP into possible securities fraud. The probe centers on a March 23 press release in which Valneva and development partner Pfizer characterized Phase 3 data for their Lyme disease vaccine candidate, LB6V, as positive. While the vaccine demonstrated over 70% efficacy, the study failed to meet its primary endpoint due to an unexpectedly low disease incidence. The market reaction was brutal: American depositary receipts plunged 37% on the day of the announcement, and the stock has continued to slide since.

The selloff has been relentless. Valneva’s shares now trade at around €2.40, just above the 52-week low touched this week. Since the start of the year, the stock has shed roughly 38% of its value, reflecting deep investor skepticism about both the clinical setback and the legal exposure.

Should investors sell immediately? Or is it worth buying Valneva?

Analyst opinions are sharply divided on the company’s prospects. Jefferies maintains a price target of $15, suggesting significant upside from current levels. Goldman Sachs takes the opposite view, rating the stock a sell with a fair value estimate of just €2.15, pointing to headwinds including the voluntary withdrawal of Valneva’s chikungunya vaccine Ixchiq from the US market.

Despite the statistical disappointment, the Lyme disease program is far from abandoned. Pfizer remains committed to the candidate, which is the only late-stage Lyme vaccine in clinical development globally. The partners still plan to file for regulatory approval with the FDA and European Medicines Agency in the second half of this year. Success would unlock milestone payments of up to $143 million and double-digit percentage royalties.

Valneva’s near-term financial outlook is more subdued. Management has guided for full-year revenue of no more than €170 million, down from roughly €175 million last year. The decline is primarily attributed to the phase-out of third-party product sales, though the company’s own travel vaccine business is expected to grow.

For the first quarter, Guggenheim analysts project revenue of around €49 million, a figure that would comfortably exceed consensus estimates. But the earnings call will be about more than just the numbers. Investors are demanding concrete timelines — particularly for the Lyme vaccine submission and the release of Phase 2 data for Valneva’s shigellosis candidate, both expected in the second half of the year. The management team will also need to address the legal probe head-on and provide clarity on how long the existing cash reserves can sustain operations without additional financing.

Ad

Valneva Stock: New Analysis - 8 May

Fresh Valneva information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Valneva analysis...

en | FR0004056851 | VALNEVA | boerse | 69292106 |